VS 01

Drug Profile

VS 01

Alternative Names: VS-01

Latest Information Update: 18 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Versantis
  • Class Tricarboxylic acids
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver failure
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Inborn urea cycle disorders; Liver failure

Most Recent Events

  • 17 Jul 2017 VS 01 receives Orphan Drug status for Liver failure (Acute-on-Chronic) in USA
  • 30 Nov 2016 VS 01 receives Orphan Drug status for Liver failure before November 2016 (Versantis website, November 2016)
  • 01 Mar 2016 Preclinical trials in Inborn urea cycle disorders in Switzerland (Intraperitoneal) before March 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top